双膦酸盐辅助治疗在早期乳腺癌患者中的应用.pptVIP

ABCSG-12实验中骨的亚组研究 骨密度改变百分比 从基线到６０个月的骨密度改变 (腰椎) 骨亚组研究总结 在绝经前乳腺癌患者中，LHRH 类似物和他莫昔芬或阿那曲唑基础上的辅助内分泌治疗导致明显的骨丢失 (平均减少 11.3%). 通过５年随访后 (内分泌治疗结束２年) BMD 部分恢复。然而, 与基线相比，患者骨密度仍然较低 (-6.3%). 唑来膦酸4mg ，每６个月一次可以阻止骨丢失。在唑来膦酸治疗组，与基线相比，平均BMD 增加4% 。 * * * * Zoledronic acid improved disease-free survival by a relative 36% (P = .012) compared with placebo over 84 months with a median follow-up of 60 months Patients treated with zoledronic acid experienced only 54 events compared with 83 events experienced in patients with no zoledronic acid These results may reflect the antitumor activity of zoledronic acid and its potential to alter the disease course for patients with early cancer Reference Gnant M, Mlineritsch B, Schippinger W, et al. Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12. Presented at: 44th Annual Meeting of the American Society of Clinical Oncology. May 30-June 3, 2008;Chicago, IL. Abstract LBA4. * * ZOL significantly improved relapse-free survival compared with no ZOL RFS endpoint included local recurrence, contralateral breast cancer, distant metastases, or secondary carcinoma This is every event included in DFS except death ZOL produced a trend towards increased overall survival versus no ZOL Reference Gnant M, Mlineritsch B, Schippinger W, et al. Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12. Presented at: 44th Annual Meeting of the American Society of Clinical Oncology. May 30-June 3, 2008;Chicago, IL. Abstract LBA4. * * * * * * * Zoledronic acid effectively delays bone metastases, non-bone metastases, contralateral and locoregional recurrence These effects could result from both direct and indire